Posted on 20/10/2009 in Medical Company Financials Boston Scientific, the manufacturer of medical instruments, has posted its financial results for the third quarter of 2009.
The firm has revealed that it experienced a three per cent growth in sales during the period, bringing this figure up to $2.02 billion (1.23 billion pounds).
It has also retained its position as the leading manufacturer of drug-eluting stents (DES), holding a 41 per cent share in the global market.
The company's worldwide cardiac rhythm management product sales rose by eight per cent, while its endoscopy sales increased by ten per cent during the quarter.
Ray Elliott, president and chief executive officer of Boston Scientific, stated: "In DES, we maintained our worldwide leadership position. A key component of that leadership has been our Taxus franchise, which has been studied in more than 46,000 patients over the past nine years."
Earlier this month, Boston Scientific announced that three models of its WallFlex Biliary RX Covered Stents would be made available for purchase in both Europe and the US.
Other news stories from 20/10/2009
Read more in the Zenopa News Archive
How this news is generated
|
